Back to top
more

Merus (MRUS)

(Delayed Data from NSDQ)

$56.99 USD

56.99
724,212

+0.21 (0.37%)

Updated Jun 26, 2024 04:00 PM ET

After-Market: $57.04 +0.05 (0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merus N.V. (MRUS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lilly (LLY) Inks Deal With Merus to Discover Cancer Antibodies

by Zacks Equity Research

Eli Lilly (LLY) signs a deal with Merus to develop novel T-cell re-directing bispecific antibodies. While Merus will lead early-stage development, Loxo Oncology will take care of further development and commercialization.

Company News for Jan 11, 2021

by Zacks Equity Research

Companies in the news are: CMRX, GSAT, MRUS, FFIV

Merus (MRUS) Stock Up on FDA's Fast Track Tag for Zenocutuzumab

by Zacks Equity Research

The FDA bestows a Fast Track status to Merus' (MRUS) lead pipeline candidate, Zenocutuzumab, for treating metastatic solid tumors harboring NRG1 gene fusions. Shares rise.

Merus (MRUS) Looks Good: Stock Adds 7% in Session

by Zacks Equity Research

Merus (MRUS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Merus NV (MRUS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Merus NV (MRUS) delivered earnings and revenue surprises of -25.93% and -21.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Merus N.V. (MRUS) delivered earnings and revenue surprises of 14.89% and 15.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Can European Buyouts Aid Canopy Growth's (CGC) Q2 Earnings?

by Zacks Equity Research

Canopy Growth (CGC) acquires a number of European companies to expand its production base across a region that promises great opportunities.

Can Cannabis Therapy Drive Canopy Growth's (CGC) Q2 Earnings?

by Zacks Equity Research

A series of acquisitions is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal second quarter.

Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Merus N.V. (MRUS) delivered earnings and revenue surprises of -5.56% and -27.29%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Acorda (ACOR) posts narrower-than-expected loss while revenues top estimates in the second quarter. Inbrija delivers a solid start with sales rising sequentially.

Moving Average Crossover Alert: Merus

by Zacks Equity Research

Merus is looking like an interesting pick from a technical perspective.

NuCana Initiates Dosing in Phase I Study for Solid Tumors

by Zacks Equity Research

NuCana (NCNA) doses the first patient in a phase I study on NUC-7738, which is being evaluated for the treatment of advanced solid tumors.

Will Merus N.V. (MRUS) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moleculin Files New Patents for Cancer Candidate Annamycin

by Zacks Equity Research

Moleculin (MBRX) petitions for new patents to cover annamycin, currently being developed for treating patients with relapsed or refractory acute myeloid leukemia. Shares rise.

Moving Average Crossover Alert: Merus

by Zacks Equity Research

Merus N.V. (MRUS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Inovio Ends Enrollment in Vulvar Dysplasia Study on VGX-3100

by Zacks Equity Research

Inovio (INO) closes enrollment in the phase II study, evaluating VGX-3100 for the treatment of HPV-related vulvar dysplasia.

Nabriva Gets EMA Acceptance for Pneumonia Drug Lefamulin

by Zacks Equity Research

The EMA endorses Nabriva Therapeutics' (NBRV) marketing application for both the intravenous and oral formulations of lefamulin to treat adult patients with community-acquired pneumonia.

Vertex's (VRTX) Symdeko Gets FDA Nod for Use in Children

by Zacks Equity Research

Vertex's (VRTX) Symdeko gets FDA approval to treat underlying cause of cystic fibrosis in children aged 6-11 years with certain mutations in the CFTR gene.

Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study

by Zacks Equity Research

Akari (AKTX) presents favorable safety data from part A of an early-stage study on nomacopan for treating moderate to severe atopic keratoconjunctivitis. Shares appreciate.

Merus N.V. (MRUS) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Merus N.V. (MRUS).

Intrexon Up on Striking 100M Cannabinoid Deal With Surterra

by Zacks Equity Research

Intrexon (XON) inks a $100-million worth exclusive licensing deal with Surterra to produce cannabinoid in a reliable and cost-effective fashion, using its own yeast fermentation process. Shares climb.

Athenex Rallies on Positive Early Data on Psoriasis Candidate

by Zacks Equity Research

Athenex (ATNX) shares rise on encouraging preliminary data from an early-stage study on KX2-391, currently under development for treating patients with psoriasis.

Reata's (RETA) Kidney Candidate Gets Orphan Drug Status

by Zacks Equity Research

The FDA bestows an orphan drug designation on Reata Pharmaceuticals' (RETA) candidate, bardoxolone, for treating patients with autosomal dominant polycystic kidney disease.

Agios' Tibsovo Meets Endpoint in Cholangiocarcinoma Study

by Zacks Equity Research

Agios' (AGIO) Tibsovo achieves the primary goal in a late-stage development that examined it for the previously treated IDH1 mutant cholangiocarcinoma. Shares rise in after-hours trading.